Outcome of Board Meeting held on Saturday 30th May, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
BIOFILCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biofil Chemicals & Pharmaceuticals Ltd has released its audited financial results for Q4 and FY ended March 31, 2026. The company reported total revenue of Rs 2,839.52 Lakhs, down 15% from Rs 3,340.22 Lakhs in the previous year due to partial disruption in manufacturing operations caused by factory renovation and upgradation under revised Schedule M (Drug & Cosmetics Rules). However, net profit surged nearly 5x to Rs 278.60 Lakhs from Rs 55.78 Lakhs, primarily boosted by a one-time gain from sale of the Sanwer Road undertaking to Formo Plast Private Limited. Basic EPS improved to Rs 1.71 from Rs 0.34. The auditors (Maheshwari & Gupta) issued an unmodified opinion, confirming clean financials. Total assets declined to Rs 4,284.81 Lakhs from Rs 5,096.04 Lakhs, while equity increased to Rs 2,156.43 Lakhs. Net cash increased by Rs 307.11 Lakhs during the year.
The stock shows mixed signals: strong profit growth driven by one-time asset sale is positive, but declining revenue from ongoing operations and factory disruptions may concern investors. The clean audit opinion supports financial reliability, though the company needs to address operational challenges from factory renovation.